VIVS (Organovo) סך נכסי הפעילות העסקית

VivoSim Labs Inc (VIVS) is integrating 3D tissue printing systems into preclinical drug trials, ensuring steady revenue through long-term B2B agreements. The delivery of living structures relies on specialized temperature-controlled transport. The company is currently restructuring its operations, resulting in total assets amounting to 7.91. The historical price action for this metric is illustrated in the chart below.

Total assets represent the aggregate of a company's resources, calculated inversely via return on assets (ROA) as the sum of equity and liabilities. By analyzing asset trends through ROA, an investor assesses the efficiency of the base in generating profit, which is critically important for VivoSim Labs Inc (VIVS) given the high cost of 3D bioprinting development and the prolonged timelines for technology commercialization.